Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea

Headache

Volumn 52, Issue 2, 2012, Pages 204-212

  Schulman, Elliot A ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

gastrointestinal; migraine; nausea; sumatriptan; transdermal; vomiting

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; PLACEBO; SUMATRIPTAN;

ADULT; AGED; ANALGESIA; APPLICATION SITE REACTION; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; NAUSEA AND VOMITING; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; IONTOPHORESIS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NAUSEA; PAIN MEASUREMENT; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SUMATRIPTAN; TIME FACTORS; YOUNG ADULT;

EID: 84857057091     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.02065.x     Document Type: Article

References (31)

1. Lance J, Anthony MB,. Some clinical aspects of migraine. Arch Neurol. 1966; 15: 356-361.
2. Silberstein SD,. Migraine symptoms: Results of a survey of self-reported migraineurs. Headache. 1995; 35: 387-396.
3. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 1-160.
4. US Headache Consortium. US Headache Consortium guidelines. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. Available at: (accessed May 2011).
5. Llewelyn JG, Findley LJ, Gross ML,. Migraine symptoms: Which cause the most distress? In:, Olesen J, Tfelt-Hansen P, eds. Headache Treatment: Trial Methodology and New Drugs. Philadelphia, PA: Lippincott-Raven; 1997: 153-156.
6. Lipton RB, Pascual J, Goadsby P,. Effect of rizatriptan and other triptans on the nausea symptom of migraine: A post hoc analysis. Headache. 2001; 41: 754-763. (Pubitemid 32953325)
7. Tkachuk GA, Cottrell CK, Gibson JS, O'Donnell FJ, Holroyd KA,. Factors associated with migraine-related quality of life and disability in adolescents: A preliminary investigation. Headache. 2003; 43: 950-955. (Pubitemid 37238649)
8. Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Almas M, Parsons B,. Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database. Cephalalgia. 2008; 28: 35-40. (Pubitemid 350212650)
9. Pfaffenrath V, Scherzer S,. Analgesics and NSAIDs in the treatment of the acute migraine attack. Cephalalgia. 1995; 15 (Suppl. 15): 14-20.
10. Johnson ES, Ratcliffe DM, Wilkinson M,. Naproxen sodium in the treatment of migraine. Cephalalgia. 1985; 5: 5-10. (Pubitemid 15104389)
11. Saadah HA,. Abortive migraine therapy with oral naproxen sodium plus metoclopramide plus ergotamine tartrate with caffeine. Headache. 1992; 32: 95-97.
12. Longmore J, Dowson AJ,. Advances in migraine therapy-5HT receptor subtype-specific agonist drugs. Curr Opin CPNS Invest Drugs. 1999; 1: 39-53.
13. MacGregor EA, Brandes J, Eikermann A,. Migraine prevalence and treatment patterns: The global migraine and zolmitriptan evaluation survey. Headache. 2003; 43: 19-26. (Pubitemid 36150986)
14. Malik SN, Hopkins M, Young WB, Silberstein SD,. Acute migraine treatment: Patterns of use and satisfaction in a clinical population. Headache. 2006; 46: 773-780.
15. Rodgers AJ, Hustad CM, Cady RK, et al,. Total migraine freedom, a potential primary endpoint to assess acute treatment in migraine: Comparison to the current FDA requirement using the complete rizatriptan study database. Headache. 2011; 51: 356-368.
16. Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T,. Zelrix: A novel transdermal formulation of sumatriptan. Headache. 2009; 49: 817-825.
17. Wilks K, Pierce M, O'Neill C, Angelov AS, Du W, Safirstein B,. Pharmacokinetics of oral and transdermal sumatriptan during acute migraine and non-migraine periods: Incidence of the migraine effect. Poster PO-55. Presented at American Headache Society, June 24-27, 2010; Los Angeles, CA.
18. Goldstein J, Pugach N, Smith T, Nett R, Angelov A, Pierce M,. Acute anti-migraine efficacy and tolerability of Zelrix, a novel iontophoretic transdermal patch of sumatriptan. Cephalalgia. 2009; 29 (Suppl. 1): 20.
19. Schulman S, O'Neill C, Pierce M, Griesser J, Angelov AS,. Efficacy of transdermal sumatriptan, a novel iontophoretic transdermal sumatriptan patch, in the treatment of acute migraine in patients with nausea. Poster PO-57. Presented at the American Headache Society, June 24-27, 2010; Los Angeles, CA.
20. Siegel SJ, O'Neill C, Dube LM, et al,. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res. 2007; 24: 1919-1926. (Pubitemid 47389248)
21. Pryse-Phillips W, Aubé M, Bailey P, et al,. A clinical study of migraine evolution. Headache. 2006; 46: 1480-1486. (Pubitemid 44722185)
22. Lipton RB, Hamelsky SW, Dayno JM,. What do patients with migraine want from acute migraine treatment? Headache. 2002; 42 (Suppl. 1): 3-9.
23. Lipton RB, Laska EM, Baggish JS, Hoffman HD, Battikha JP, Mellace DR,. What symptoms cause migraineurs to treat? Presented at the American Headache Society, June 19-22, 2003; Chicago, IL.
24. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S,. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache. 1998; 38: 184-190. (Pubitemid 28173759)
25. Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M,. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med. 1998; 7: 234-240. (Pubitemid 128433246)
26. Lipton RB, Dodick DW, Adelman JU, et al,. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia. 2009; 29: 826-836.
27. Ferrari MD, Loder E, McCarroll KA, Lines CR,. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia. 2001; 21: 129-136. (Pubitemid 32575476)
28. Freitag F, Taylor FR, Hamid MA, et al,. Elimination of migraine-associated nausea in patients treated with rizatriptan orally disintegrating tablet (ODT): A randomized, double-blind, placebo-controlled study. Headache. 2008; 48: 368-377. (Pubitemid 351517785)
29. Worthington I,. Delivery systems for acute migraine medications. Can Fam Physician. 2001; 47: 322-329. (Pubitemid 32208813)
30. Cady RK, Sheftell F, Lipton RB, et al,. Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials. Clin Ther. 2000; 22: 1035-1048.
31. Rapoport AM,. New acute treatments for headache. Neurol Sci. 2010; 31 (Suppl. 1): 129-132.